TargetMol

Melflufen

Product Code:
 
TAR-T33281
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33281-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33281-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33281-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Melphalen fluoroaniline, also known as melphalen, J-1, or prodrug J-1, is a prodrug of melphalen, in which the alkylating agent melphalen is combined with fluoroaniline and has potential antitumor and antiangiogenic activities.
CAS:
380449-51-4
Formula:
C24H30Cl2FN3O3
Molecular Weight:
498.42
Purity:
0.98
SMILES:
CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(cc1)N(CCCl)CCCl

References

Viktorsson K, Shah CH, Juntti T, H??g P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ull?n A. Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. Mol Oncol. 2016 Jan 2. pii: S1574-7891(15)00249-5. doi: 10.1016/j.molonc.2015.12.013. [Epub ahead of print] PubMed PMID: 26827254. Berglund ?, Ull?n A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordstr?m E, S?derlind K, Gullbo J. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10. PubMed PMID: 26553306. Strese S, Wickstr?m M, Fuchs PF, Frykn?s M, Gerwins P, Dale T, Larsson R, Gullbo J. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo. Biochem Pharmacol. 2013 Oct 1;86(7):888-95. doi: 10.1016/j.bcp.2013.07.026. Epub 2013 Aug 8. PubMed PMID: 23933387. Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 1;19(11):3019-31. doi: 10.1158/1078-0432.CCR-12-3752. Epub 2013 Apr 12. PubMed PMID: 23584492; PubMed Central PMCID: PMC4098702.